Immunogenicity and safety of an Escherichia coli-produced 9-valent human papillomavirus vaccine (types 6/11/16/18/31/33/45/52/58) in healthy Chinese women aged 20–45 years: a single-center, randomized, observer-blinded, positive controlled phase 2 clinical trial
Mingwei Wei(Jiangsu Provincial Center for Disease Control and Prevention), Jingxin Li(Jiangsu Provincial Center for Disease Control and Prevention), Weiwei Han(Nanjing Medical University), Hongyan Liu(Shanghai Institutes for Biological Sciences), Wenjuan Wang(Key Laboratory of Guangdong Province), Jing Zhang(Children's Hospital of Fudan University), Hongxing Pan(Jiangsu Provincial Center for Disease Control and Prevention), Huilong Yu(Beijing Red Cross Blood Center), Dan Wu(Shanghai Children's Medical Center)
Cited by 1
Related Papers
Hand, foot, and mouth disease in China, 2008–12: an epidemiological study
|The Lancet Infectious Diseases|2014|977
An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of Hand Foot and Mouth Disease in Fuyang city of China
|Virology Journal|2010|473
MicroRNA identification based on sequence and structure alignment
|Bioinformatics|2005|287